
French Sanofi has been granted Priority Review by the US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the indication for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus, the company has announced in a press release.
The FDA’s Priority Review designation enables a faster regulatory pathway, cutting down case processing to around six months from the usual ten.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app